| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.18 | 0.3 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.03 | 0.3 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |